Savolitinib, AstraZeneca Complete Enrolment for Phase II Clinical Trial in Papillary Renal Cell Carcinoma

By: via Benzinga
Hutchison China MediTech Limited (OTC: HNCMF) today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.